Journal Article

Steroid Hormone Receptor Status of Mouse Mammary Stem Cells

Marie-Liesse Asselin-Labat, Mark Shackleton, John Stingl, François Vaillant, Natasha C. Forrest, Connie J. Eaves, Jane E. Visvader and Geoffrey J. Lindeman

in JNCI: Journal of the National Cancer Institute

Volume 98, issue 14, pages 1011-1014
Published in print July 2006 | ISSN: 0027-8874
Published online July 2006 | e-ISSN: 1460-2105 | DOI:
Steroid Hormone Receptor Status of Mouse Mammary Stem Cells

Show Summary Details


The estrogen receptor α (ERα), progesterone receptor (PR), and erbB2 (Her2 in humans) are important prognostic markers of human breast cancer, and they are variably expressed in different subtypes of breast cancer. The basal subtype, for example, is negative for ERα, PR, and Her2 by immunohistochemistry. We investigated the expression of these signaling molecules in enriched populations of mouse mammary stem cells and luminal cells that were isolated according to their differential expression of CD24 and the α6β1-integrin complex. We found that the basal population, which is enriched in mouse mammary stem cells, did not express ERα, PR, or ErbB2/Her2 but did express epidermal growth factor receptor (EGFR)/ErbB1, whereas the subset of cells enriched for luminal cells expressed ERα (37% of cells) and PR (40% of cells) but not ErbB2/Her2 or EGFR/ErbB1. Ovariectomy confirmed the importance of estrogen signaling to luminal cell proliferation but had no effect on the size of the mouse mammary stem cell-enriched population. Thus, mouse mammary stem cells were negative for ERα, PR, and ErbB2 and appeared to share common properties with poor-prognosis basal breast cancer.

Journal Article.  2667 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.